2025-10-03 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co. (LLY) based on the data you provided. I'll format it as a report with key metrics, analysis, and a conclusion.

**Eli Lilly and Co. (LLY) Stock Analysis**

**Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

**1. Performance vs. S&P 500 (VOO)**

*   **LLY Cumulative Return:** 180.12%
*   **VOO Cumulative Return:** 97.56%
*   **Absolute Spread:** 82.6
*   **Relative Spread:** 41.2 (This indicates LLY's outperformance is in the upper range of its historical spread relative to the S&P 500).
*   **Interpretation:** LLY has significantly outperformed the S&P 500. The relative spread suggests this outperformance is substantial compared to its historical trends.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha  | Beta  | Cap(B) |
|------------|---------|---------|--------|-------|--------|
| 2015-2017  | 11.0%   | 76.1%   | -17.0% | -0.0  | 75.8   |
| 2016-2018  | 39.0%   | 68.9%   | 24.0%  | -0.0  | 103.8  |
| 2017-2019  | 41.0%   | 68.9%   | 19.0%  | 0.4   | 117.9  |
| 2018-2020  | 34.0%   | 79.8%   | 10.0%  | 0.4   | 151.4  |
| 2019-2021  | 53.0%   | 79.8%   | 7.0%   | 0.5   | 247.7  |
| 2020-2022  | 64.0%   | 79.8%   | 65.0%  | 0.4   | 328.1  |
| 2021-2023  | 125.0%  | 78.9%   | 124.0% | 0.2   | 522.8  |
| 2022-2024  | 134.0%  | 81.2%   | 113.0% | 0.2   | 692.4  |
| 2023-2025  | 71.0%   | 83.5%   | 9.0%   | 0.2   | 652.6  |

*   **CAGR:**  The Compound Annual Growth Rate has been very strong, especially in recent periods (2021-2024).
*   **MDD:** Maximum Drawdown is high, indicating significant price volatility, but seems reasonable considering high CAGR.
*   **Alpha:**  Alpha, representing excess return over the benchmark, is very high for some periods, particularly 2020-2024, suggesting significant outperformance independent of market movements.  The negative alpha in the 2015-2017 period stands out as an underperformance compared to the benchmark.
*   **Beta:** Beta values are low (close to zero), indicating that the stock is not strongly correlated with the market.
*   **Cap(B):**  Market capitalization has grown substantially.
*   **Interpretation:** The data suggests that LLY has delivered strong growth and substantial outperformance, especially recently. High Alpha indicates that much of the return is due to company-specific factors rather than market movements. The stock is not strongly correlated with the market based on its beta.

**2. Recent Price Action**

*   **Current Price:** 727.68
*   **Last Market Data:**
    *   Price: 819.85
    *   Previous Close: 825.42
    *   Change: -0.67
*   **5-Day Moving Average:** 730.40
*   **20-Day Moving Average:** 744.67
*   **60-Day Moving Average:** 742.08

*   **Interpretation:** The recent price is below all the moving averages (5, 20, and 60 days), suggesting a short-term downtrend. The price change in the last market session is small.

**3. Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 39.08 (Approaching oversold, but not yet there)
*   **PPO:** -0.53 (Negative, suggesting a potential downtrend)
*   **Delta_Previous_Relative_Divergence:** -3.4 (Negative, indicating a recent short-term decline in relative performance)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (Strong Buy Signal based on the model).
*   **Expected Return:** 181.3% (Long-term, relative to S&P 500)
*   **Interpretation:** Despite the recent price weakness, the MRI indicates high investment recommendation. The RSI is not yet in oversold territory, and the PPO suggests potential downward momentum. The hybrid signal indicates a strong buy recommendation. The expected return is substantial, implying strong future growth potential relative to the S&P 500.

**4. Recent News & Significant Events**

*   **Centene, QuidelOrtho, iRhythm, and Bio-Techne Shares Skyrocket:** This suggests broader positive trends in the healthcare sector.
*   **agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health Stocks Trade Up:** Another indicator of positive sentiment towards health-related stocks.
*   **Buy Novo Nordisk Stock:** Positive sentiment in the pharmaceutical space.
*   **Eli Lilly (LLY) Valuation: Assessing Growth Potential After U.S. Drug Pricing Policy Shift and Fresh Approvals:** Important news directly related to LLY. The article indicates that the valuation is being reassessed in light of new policies and drug approvals.  This could be a driver of future price movement.
*   **Alexandria Real Estate Equities (ARE): Assessing Valuation Following Lilly Gateway Labs Partnership in San Diego:**  This highlights collaborations and expansion efforts, which are generally positive signs.
*   **LEXX: Biodistribution Study Results:**  This likely pertains to another company, not directly related to LLY.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.78 (Buy)
*   **Number of Opinions:** 26
*   **Target Price:**
    *   Average: 888.15
    *   High: 1190.00
    *   Low: 650.00

*   **Interpretation:** Analyst sentiment is strongly positive, with a consensus "Buy" rating and a substantial average target price significantly above the current price.  The wide range between the high and low target prices suggests some uncertainty.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue       |
|------------|-------|---------------|
| 2025-08-07 | 6.3   | 15.56 B$      |
| 2025-05-01 | 3.07  | 12.73 B$      |
| 2024-10-30 | 1.08  | 11.44 B$      |
| 2024-08-08 | 3.29  | 11.30 B$      |
| 2025-08-07 | 3.29  | 11.30 B$      |

*   **Interpretation:** The most recent earnings (2025-08-07) show very strong EPS and revenue. There's a clear upward trend in both EPS and revenue over the past few quarters, indicating strong growth.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $15.56B   | 84.27%        |
| 2025-03-31 | $12.73B   | 82.53%        |
| 2024-12-31 | $13.53B   | 82.24%        |
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-06-30 | $18.27B   | 30.98%   |
| 2025-03-31 | $15.76B   | 17.50%   |
| 2024-12-31 | $14.19B   | 31.07%   |
| 2024-09-30 | $14.24B   | 6.81%    |
| 2024-06-30 | $13.56B   | 21.88%   |

*   **Interpretation:** Revenue and Profit Margin are consistently high and trending upward. The Return on Equity (ROE) is also strong, indicating efficient use of shareholder equity to generate profits. Equity itself is increasing, suggesting healthy financial management.

**7. Overall Assessment**

LLY demonstrates the following key characteristics:

*   **Strong Outperformance:**  Significantly outperformed the S&P 500, with a relative spread indicating this outperformance is historically significant.
*   **High Growth:**  Strong CAGR, increasing revenue, and EPS indicate robust growth.
*   **High Profitability:**  Excellent profit margins and ROE point to efficient operations.
*   **Positive Sentiment:** Analysts have a consensus "Buy" rating with a target price well above the current level.
*   **Recent Weakness:**  Recent price action suggests a short-term downtrend, but this may be a temporary pullback.
*   **High Investment Recommendation:** The MRI indicator suggests that the stock is suitable for investment.
*   **Valuation Considerations:** The news articles highlight ongoing valuation assessments, especially in light of new policies and drug approvals, which could influence future price movements.

**Conclusion**

Based on the provided data, Eli Lilly and Co. (LLY) appears to be a fundamentally strong company with significant growth potential. While there's some recent price weakness, the overall picture is positive, supported by strong financial performance, analyst sentiment, and market risk indicators. The high expected return reinforces the potential for long-term investment. Pay close attention to news regarding valuation assessments and drug approval developments, as these can impact future price action.
